by As the global population ages, the prevalence of age-related muscle loss or sarcopenia is rising rapidly. Sarcopenia is a condition characterized by the loss of skeletal muscle mass and strength which increases the risk of adverse outcomes including physical disability, poor quality of life and death. The mainstay of sarcopenia treatment involves protein supplementation, exercise therapy and other anabolic therapies to help build or preserve muscle mass. Protein supplements containing essential amino acids aid in stimulating muscle protein synthesis while resistance and weight training exercises stimulate muscle growth. Several pharmaceutical agents targeting different pathways involved in muscle loss are also under development.
The global Sarcopenia Treatment Market is estimated to be valued at US$ 3.01 Bn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the main trends in the sarcopenia treatment market is the development of novel anabolic agents. Typically, available therapies only aim to slow down muscle loss but newer drugs are focusing on stimulating new muscle growth. Some classes of drugs under research include myostatin inhibitors, selective androgen receptor modulators (SARMs) and ghrelin receptor agonists. Myostatin naturally inhibits muscle growth and blocking its action has shown promise in animal studies. SARMs selectively activate the androgen receptor in muscles with minimal effect on other tissues. Ghrelin is a gut hormone that stimulates appetite and growth hormone secretion. Ghrelin receptor agonists may help build new muscles. These novel agents present significant commercial opportunities if clinical trials demonstrate their efficacy and safety in age-related muscle wasting conditions like sarcopenia.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate due to high capital requirement for R&D and manufacturing. However, opportunities exist for new companies developing innovative treatment approaches.
Bargaining power of buyers: The bargaining power of buyers is moderate as there are several treatment options available and customers can switch between brands easily.
Bargaining power of suppliers: The bargaining power of suppliers is low as there are many raw material suppliers and manufacturers in the market.
Threat of new substitutes: The threat of new substitutes is high due to vast pipeline of novel therapeutics and treatment options in clinical trials.
Competitive rivalry: The competitive rivalry in the sarcopenia treatment market is high due to presence of major pharmaceutical players.
Key Takeaways
The global Sarcopenia Treatment Market Share is expected to witness high growth. North America dominates the sarcopenia treatment market currently due to advanced healthcare infrastructure and increasing elderly population suffering from sarcopenia. Asia Pacific is expected to grow at the fastest pace during the forecast period attributed to large patient pool and rising health awareness in the region.
Key players related content comprises Key players operating in the (sarcopenia treatment) are Abbott Laboratories, Novartis AG, Eli Lilly and Company, Merck & Co., Inc., GlaxoSmithKline plc.The major players focuses on new product launches and collaborations to strengthen their market position. For instance, in 2021, Eli Lilly and Company collaborated with Atomwise to develop novel therapies for sarcopenia.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
